9 matches for your search in the start-up spotlight
rssSURI BioTech is a biotechnology company, developing health promoting bacterial strains with targeted mechanisms of action for the first 1000 days of life. Our proprietary strains are natural and safe and can be included in food supplements for pregnant women, mothers and newborns. Our lead ...
SURI BioTech is a biotechnology company, developing health promoting bacterial strains with targeted mechanisms of action for the first 1000 days of life. Our proprietary strains are natural and safe and can be included in food supplements for pregnant women, mothers and newborns. Our lead ...
LimmaTech Biologics AG is a Swiss clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antimicrobial resistance (AMR) and sexually transmitted diseases. LimmaTech was founded in 2015 as a ...
Personalized, bio-engineered, dermo-epidermal skin grafts. CUTISS is a Swiss clinical-stage life sciences company focussed on skin regenerative medicine and tissue engineering. It is developing the first personalized and automated skin tissue therapy offering life-saving and life-changing ...
At Anjarium Biosciences, we are striving to create and deliver solutions for patients beyond what current gene therapy platforms address today. We do this by tackling more diseases, more precisely and in a more personalized way. Anjarium is developing a new generation of genetic medicines to ...
CDR-Life is a Zurich-based biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology and ophthalmology. Our facilities are located in the Bio-Technopark in Schlieren-Zurich, Switzerland.
Elthera AG is developing antibodies against the novel target L1CAM, an adhesion molecule whose expression is strongly correlated with an aggressive tumor phenotype and poor prognosis in various types of cancer. Inhibition of L1CAM targets many mechanisms of tumor progression such as resistance to ...
Memo Therapeutics AG (”MTx”) is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with virus infections and cancer. MTx’ lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney ...